Seizure News and Research

Latest Seizure News and Research

Americans to join in Purple Day campaign to support epilepsy awareness

Members of the U.S. House and Senate, children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26. Thousands of Americans will also join the campaign by hosting Purple Day activities in their regions.

22 Mar 2010

Study results of Medtronic DBS Therapy for epilepsy published in Epilepsia

Medtronic, Inc. today announced that a landmark publication highlighting results from the pivotal study for Medtronic Deep Brain Stimulation (DBS) Therapy for epilepsy, known as SANTE® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy), was published online today in the medical journal, Epilepsia. The SANTE study, sponsored by Medtronic, is the largest and most rigorous clinical study of DBS therapy for epilepsy in adults with medically refractory epilepsy with partial-onset seizures.

19 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

SANTE study: Deep brain stimulation can reduce seizures

A recent study organized by Stanford University researchers found patients with refractory partial and secondarily generalized seizures had a reduction in seizures after deep brain stimulation. This multi-center clinical trial determined that the benefits of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE) persisted and by 2 years there was a 56% reduction in seizure frequency.

18 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

FDA Neurological Devices Panel recommends approval of DBS Therapy for epilepsy

The U.S. Food and Drug Administration Neurological Devices Panel today voted seven to five to recommend approval with conditions of Deep Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy.

15 Mar 2010

ATS releases new clinical policy statement on CCHS

The American Thoracic Society has released a new official clinical policy statement on congenital central hypoventilation syndrome (CCHS), a disorder of respiratory and autonomic nervous system (ANS) regulation. The ANS regulates reflexive acts, including heart rate and blood pressure, digestion, body temperature and pain perception.

15 Mar 2010

Landmark clinical trial examines effective treatment options for childhood epilepsy

One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.

15 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Does Medicare 'doughnut hole' spur increase in foreign drug imports?

Medill Reports: "Unless federal legislation closes the Medicare coverage gap colloquially known as the 'doughnut hole,' seniors may opt for online drug imports to alleviate steep prescription costs. ... 'As seniors start falling into the doughnut hole, they are going online to find deals on prescription drugs, whether they're based in the U.S. or in other countries,' said Gabriel Levitt, vice president of PharmacyChecker.com LLC, a leader in the evaluation of online and mail-order pharmacies in both the U.S. and abroad.

12 Mar 2010

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Many Americans will lose an hour of sleep on March 14, the first day of daylight-saving time, when clocks are set ahead one hour at 2 a.m. local standard time—making it harder to wake up, causing difficulty in staying alert and increasing the chance of sleepy-driving car crashes.

11 Mar 2010

Winners of NMSIS scholarship award

Two winners have been selected for the Promising New Investigators Travel Scholarship Awards given annually by the Neuroleptic Malignant Syndrome Information Service (NMSIS).

10 Mar 2010

Clinical and scientific advances made in the field of neuro-oncology

Many important clinical and basic scientific advances have been made in the past five years in the field of neuro-oncology, according to an editorial and several articles in the March issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Mar 2010

'Fake pot' can cause hallucinations and seizures

In the last month, Anthony Scalzo, M.D., professor of toxicology at Saint Louis University, has seen nearly 30 cases involving teenagers who were experiencing hallucinations, severe agitation, elevated heart rate and blood pressure, vomiting and, in some cases, tremors and seizures.

4 Mar 2010

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy.

4 Mar 2010

NAEC elects Mayo Clinic as top epilepsy treatment center

Mayo Clinic has been designated a comprehensive epilepsy treatment center by the National Association of Epilepsy Centers (NAEC). Only the top epilepsy programs - those that can provide the most complex and advanced care - are selected for this designation, according to the association.

3 Mar 2010

Toxins in K2: Saint Louis University professor warns parents to lookout for warning signs

3 Mar 2010

Seizure News and Research

Latest Seizure News and Research

Americans to join in Purple Day campaign to support epilepsy awareness

Study results of Medtronic DBS Therapy for epilepsy published in Epilepsia

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

SANTE study: Deep brain stimulation can reduce seizures

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

FDA Neurological Devices Panel recommends approval of DBS Therapy for epilepsy

ATS releases new clinical policy statement on CCHS

Landmark clinical trial examines effective treatment options for childhood epilepsy

New MMMCC center improves patients’ access to medical marijuana

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

Does Medicare 'doughnut hole' spur increase in foreign drug imports?

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Winners of NMSIS scholarship award

Clinical and scientific advances made in the field of neuro-oncology

'Fake pot' can cause hallucinations and seizures

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

NAEC elects Mayo Clinic as top epilepsy treatment center

Toxins in K2: Saint Louis University professor warns parents to lookout for warning signs

Everything you need to know about epilepsy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Seizure News and Research

Latest Seizure News and Research

Everything you need to know about epilepsy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in